Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: Results of the TARGET study

Journal of Infectious Diseases

Volumn 183, Issue 4, 2001, Pages 571-578

  Henry, Keith ^a   Wallace, Robert J ^b   Bellman, Paul C ^d   Norris, Dorece ^c   Fisher, Robin L ^e   Ross, Lisa L ^e   Liao, Qiming ^e   Shaefer, Mark S ^e  

^a REGIONS HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Center for Quality Care   (United States)

^d LENOX HILL HOSPITAL   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 0035865875     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318527     Document Type: Article

References (27)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
3. Human immunodeficiency virus protease inhibitors
4. Protease inhibitor-sparing HAART: A review of key studies
5. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
6. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
7. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
8. Abacavir
9. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
10. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors
11. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
12. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
13. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
14. Zidovudine: Five years later
15. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection